Ion Exchange’s membrane plant in Goa will soon produce advanced filtration technology that until now has been manufactured exclusively in Germany. The Indian water treatment firm announced the deal on 29th April, securing a technology transfer agreement with MANN+HUMMEL that shifts production of PVDF ultrafiltration membranes eastward.
The partnership grants Ion Exchange manufacturing rights to MANN+HUMMEL’s hollow fibre ultrafiltration systems and integrated UltraSKID platforms. Later phases will bring membrane bioreactor technology to India as well.
For MANN+HUMMEL, the move marks a significant departure. The Ludwigsburg-based company, which generated €4.5 billion in sales across 80 locations last year, has built its reputation on German engineering precision. Now it’s betting that localised manufacturing in India will cut lead times and strengthen supply resilience for customers worldwide.
The Goa facility isn’t starting from scratch. Ion Exchange established its reverse osmosis membrane plant there in 2017, part of India’s ‘Made in India’ push. That facility already produces RO membranes under the HYDRAMEM® brand. The German technology transfer expands the portfolio to include ultrafiltration and bioreactor systems—completing an integrated membrane offering that spans multiple treatment technologies.
“This collaboration is a significant milestone in delivering world-class solutions through our advanced HYDRAMEM® membrane manufacturing capabilities,” said Sridhar Padmanaban, senior vice president at Ion Exchange. “It marks an important step in our journey to deliver differentiated, high-performance and sustainable solutions to customers across global markets.”
The deal reflects broader shifts in water treatment supply chains. Membrane technology, critical for desalination and wastewater treatment in water-scarce regions, has historically been dominated by European and American manufacturers. Rising demand in Asia, coupled with pressure to reduce dependency on long-distance supply routes, is prompting technology holders to explore local manufacturing partnerships.
Membrane bioreactors, which combine biological treatment with membrane filtration, have gained traction in municipal wastewater applications. Ultrafiltration systems serve industries requiring high-purity water—pharmaceuticals, food processing, electronics manufacturing. Ion Exchange, with over 60 years in water management, already serves these sectors. The German technology adds performance credibility to its existing customer relationships.
Rohit Sathe, senior vice president and general manager of MANN+HUMMEL Water & Membrane Solutions, framed the partnership as a strategic convergence. “This partnership with Ion Exchange reflects a strong global collaboration focused on technology transfer and localised manufacturing of advanced membrane solutions,” he said. “It brings together complementary strengths to enhance the availability of high-performance filtration solutions, supporting evolving customer needs across markets.”
What remains unclear is the production capacity planned for Goa or the investment committed by either party. Neither company disclosed financial terms. Ion Exchange described the facility as “state-of-the-art” and “expanded,” suggesting recent capital expenditure, though specific figures weren’t provided.
The timing matters. Water scarcity intensifies across the Middle East, North Africa, and parts of Asia. Governments are investing heavily in desalination and wastewater recycling infrastructure. Membrane systems sit at the heart of these projects. Shorter lead times and regional manufacturing could prove decisive in winning contracts where project timelines are tight.
For MANN+HUMMEL, founded in 1941 as a filtration specialist, water represents one pillar of a diversified portfolio that includes automotive and industrial filtration. The company employs approximately 21,200 people globally. Its water and membrane division has pursued partnerships before, but the India manufacturing arrangement signals a deeper commitment to Asian markets than previous distribution agreements.
Ion Exchange, meanwhile, gains access to membrane technology that would have taken years and significant R&D investment to develop independently. The company manufactures ion exchange resins under its INDION® brand and has built engineering capabilities around system integration. Adding proven German membrane technology to that mix strengthens its competitive position against multinational rivals.
The collaboration also positions Ion Exchange to serve international markets from its Indian manufacturing base. The company already operates globally, with manufacturing and assembly facilities in multiple countries. Producing European-designed membranes in India, for export to Middle Eastern or Southeast Asian customers, potentially offers cost advantages over European or American suppliers.
Industry observers will watch whether other membrane technology holders follow MANN+HUMMEL’s lead. Localised manufacturing partnerships could reshape competitive dynamics in a sector where intellectual property has traditionally been closely guarded. Technology transfer agreements carry risks—partners can become competitors once they’ve absorbed the know-how.
Both companies emphasised the phased nature of the arrangement. Ultrafiltration production comes first. Membrane bioreactor technology follows. That staged approach suggests cautious execution, with performance milestones likely built into the agreement.
Production at the Goa facility is expected to serve both domestic Indian demand and international customers. India’s own water infrastructure needs are substantial—municipal treatment capacity lags behind urban growth, and industrial demand for process water continues rising. But the export dimension appears equally important to the partnership’s rationale.
The deal adds another data point to India’s manufacturing ambitions. Since launching ‘Make in India’ initiatives, the government has sought to attract technology partnerships that build domestic production capacity while reducing import dependence. Water treatment equipment, like renewable energy components and electronics, features prominently in that strategy.
Whether the Goa plant can match the quality and performance consistency of MANN+HUMMEL’s existing European facilities will ultimately determine the partnership’s success. Customers in demanding applications—pharmaceutical water systems, microelectronics manufacturing—will require proof before switching suppliers.
For now, the technology has been transferred. Manufacturing lines are being prepared. And a facility on India’s west coast is preparing to produce membranes that, until this year, were synonymous with German engineering.
